GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Devyser Diagnostics AB (OSTO:DVYSR) » Definitions » Debt-to-EBITDA

Devyser Diagnostics AB (OSTO:DVYSR) Debt-to-EBITDA : -5.02 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Devyser Diagnostics AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Devyser Diagnostics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr16.0 Mil. Devyser Diagnostics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr52.3 Mil. Devyser Diagnostics AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr-13.6 Mil. Devyser Diagnostics AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -5.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Devyser Diagnostics AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:DVYSR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.48   Med: 0.51   Max: 13.23
Current: -2.48

During the past 7 years, the highest Debt-to-EBITDA Ratio of Devyser Diagnostics AB was 13.23. The lowest was -2.48. And the median was 0.51.

OSTO:DVYSR's Debt-to-EBITDA is ranked worse than
100% of 101 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.76 vs OSTO:DVYSR: -2.48

Devyser Diagnostics AB Debt-to-EBITDA Historical Data

The historical data trend for Devyser Diagnostics AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devyser Diagnostics AB Debt-to-EBITDA Chart

Devyser Diagnostics AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 1.50 13.23 -0.87 -0.49 -1.85

Devyser Diagnostics AB Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -1.65 -18.53 -1.56 -5.02

Competitive Comparison of Devyser Diagnostics AB's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Devyser Diagnostics AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Devyser Diagnostics AB's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Devyser Diagnostics AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Devyser Diagnostics AB's Debt-to-EBITDA falls into.



Devyser Diagnostics AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Devyser Diagnostics AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(17.5 + 57.3) / -40.5
=-1.85

Devyser Diagnostics AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(16 + 52.3) / -13.6
=-5.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Devyser Diagnostics AB  (OSTO:DVYSR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Devyser Diagnostics AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Devyser Diagnostics AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Devyser Diagnostics AB (OSTO:DVYSR) Business Description

Traded in Other Exchanges
N/A
Address
Instrumentvagen 19, Hagersten, SWE, 126 53
Devyser Diagnostics AB is specialized in the development, manufacture and sale of market-leading genetic diagnostic kits.The products are used for complex DNA testing in the hereditary disease, oncology and post-transplantation monitoring fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.

Devyser Diagnostics AB (OSTO:DVYSR) Headlines

No Headlines